NCT01288430 - A Study of DS-2248 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2011

Primary Completion Date

February 13, 2014

Study Completion Date

February 13, 2014

Conditions

Solid TumorsNon-small Cell Lung Carcinoma

Interventions

DRUG

DS-2248

Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.

Trial Locations (9)

Unknown

Duarte

Loma Linda

Orange

Orlando

Indianapolis

Detroit

Portland

San Antonio

Seattle